- Home
- NMG vs DSGN Comparison
NMG vs DSGN Comparison
Compare NMG & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMG
- DSGN
- Stock Information
- Founded
- NMG 2011
- DSGN 2017
- Country
- NMG Canada
- DSGN United States
- Employees
- NMG N/A
- DSGN N/A
- Industry
- NMG Other Metals and Minerals
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- NMG Basic Materials
- DSGN Health Care
- Exchange
- NMG Nasdaq
- DSGN Nasdaq
- Market Cap
- NMG 448.1M
- DSGN 418.1M
- IPO Year
- NMG 2017
- DSGN 2021
- Fundamental
- Price
- NMG $2.51
- DSGN $8.78
- Analyst Decision
- NMG Strong Buy
- DSGN Buy
- Analyst Count
- NMG 3
- DSGN 1
- Target Price
- NMG $4.22
- DSGN $13.00
- AVG Volume (30 Days)
- NMG 800.4K
- DSGN 427.2K
- Earning Date
- NMG 11-12-2025
- DSGN 11-05-2025
- Dividend Yield
- NMG N/A
- DSGN N/A
- EPS Growth
- NMG N/A
- DSGN N/A
- EPS
- NMG N/A
- DSGN N/A
- Revenue
- NMG N/A
- DSGN N/A
- Revenue This Year
- NMG N/A
- DSGN N/A
- Revenue Next Year
- NMG N/A
- DSGN N/A
- P/E Ratio
- NMG N/A
- DSGN N/A
- Revenue Growth
- NMG N/A
- DSGN N/A
- 52 Week Low
- NMG $1.22
- DSGN $2.60
- 52 Week High
- NMG $6.06
- DSGN $8.89
- Technical
- Relative Strength Index (RSI)
- NMG 42.70
- DSGN 68.78
- Support Level
- NMG $2.43
- DSGN $7.25
- Resistance Level
- NMG $2.83
- DSGN $8.80
- Average True Range (ATR)
- NMG 0.24
- DSGN 0.69
- MACD
- NMG -0.03
- DSGN 0.12
- Stochastic Oscillator
- NMG 10.00
- DSGN 93.42
About NMG Nouveau Monde Graphite Inc.
Nouveau Monde Graphite Inc is a mineral exploration company. The company specializes in the exploration, evaluation, and development of mineral properties located in Quebec and is developing a natural graphite-based anode material that would qualify as battery-grade material to supply the lithium-ion industry. The company currently operates in two segments: the Matawinie Mine Project and the Battery Material Plant project.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.